LCTX

NYSEAMERICAN open

Lineage Cell Therapeutics

0.78 USD
▼-0.04-5.05%
盘后 0.94 0.00%
2026-11-20
市值
$196.95M
市盈率
144.81
EPS
-0.09
股息率
—
52 周区间
0.77 – 1.99
成交量
1.41M
Beta
1.69
目标价
5.50
52W 低 0.7752W 高 1.99
价格走势

公司简介

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It a...